YS Biopharma Co. Ltd. (NASDAQ:YS) finished Thursday with an addition of $0.38 to close at $1.16, an upside of 49.55 percent. An average of 6,751,725 shares of common stock have been traded in the last five days. There was a gain of $0.2708 in the past week. The last 20 days have seen an average of 1,743,021 shares traded, while the 50-day average volume stands at 836,006.
YS stock has decreased by -13.72% in the last month. The company shares reached their 1-month lowest point of $0.7481 on 08/23/23. Shares of the company touched a low of $0.75 and a high of $18.44 in 52 weeks. In spite of this, the price is down -93.68% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
YS Biopharma Co. Ltd. (YS) has a trailing price-to-earnings (P/E) ratio of 1.70. The stock’s beta is -0.13. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.15.
Financial Health
The quick ratio of YS Biopharma Co. Ltd. for the recent quarter was 0.50, and the current ratio was 0.50, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter. Its gross profit as reported stood at $77.69 million compared to revenue of $100.0 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, YS Biopharma Co. Ltd.’s return on assets was 8.80%.
Earnings Surprise
For the recent quarter, YS Biopharma Co. Ltd. had $42.75 million in total debt. The company posted a net income of -$41.25 million in the quarter, while revenues were grew 100.0%.
Technical Picture
From a technical analysis perspective, let’s take a brief look at YS Biopharma Co. Ltd. (YS) price momentum. RSI 9-day as of the close on 24 August was 58.93%, suggesting the stock is Neutral, with historical volatility in this time frame at 252.25%.
As of today, YS’s price is $0.8699 +29.43% or $0.2708 from its 5-day moving average. YS is currently trading -17.29% lower than its 20-day SMA and -30.76% lower than its 100-day SMA. However, the stock’s current price level is -18.42% below the SMA50.
The stochastic %K and %D were 25.28% and 10.13%, respectively, and the average true range (ATR) was 0.1326. With the 14-day stochastic at 69.00% and the average true range at 0.1143, the RSI (14) stands at 52.16%. The stock has reached -0.0479 on the 9-day MACD Oscillator while the 14-day reading was at -0.1481.
